Viridian Therapeutics to Participate in The 21st Annual Needham Virtual Healthcare Conference on April 14
April 06, 2022 08:00 ET
|
Viridian Therapeutics, Inc.
WALTHAM, Mass., April 06, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases...
Viridian Therapeutics Secures Flexible Credit Facility for Up to $75 Million From Hercules Capital
April 04, 2022 16:05 ET
|
Viridian Therapeutics, Inc.
WALTHAM, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases...
Viridian Therapeutics Doses First Subject in First-in-Human Clinical Trial Evaluating VRDN-002, a Next Generation IGF-1R Antibody for the Treatment of Thyroid Eye Disease
March 21, 2022 16:05 ET
|
Viridian Therapeutics, Inc.
- VRDN-002 incorporates clinically validated half-life extension technology to support development as a low volume subcutaneous injection that could broaden settings of care - - Top line results from...
Viridian Therapeutics to Participate in 32nd Annual Oppenheimer Healthcare Conference on March 15
March 14, 2022 16:05 ET
|
Viridian Therapeutics, Inc.
WALTHAM, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases...
Viridian Therapeutics Reports Fourth Quarter And Full Year 2021 Financial Results And Provides Corporate Updates
March 10, 2022 16:05 ET
|
Viridian Therapeutics, Inc.
-- Ongoing Phase 1/2 clinical trial for VRDN-001, an IGF-1R antibody for the treatment of Thyroid Eye Disease, is on track to report top line proof of concept data in the second quarter of 2022 -- ...
Viridian Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Host Investor Conference Call on March 10, 2022
March 03, 2022 16:16 ET
|
Viridian Therapeutics, Inc.
WALTHAM, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases...
Viridian Therapeutics to Participate in the SVB Leerink 2022 Global Healthcare Conference on February 18
February 14, 2022 08:00 ET
|
Viridian Therapeutics, Inc.
WALTHAM, Mass., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases...
Viridian Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate Clinical Development of VRDN-002, a Next Generation IGF-1R Antibody for the Treatment of Thyroid Eye Disease
January 31, 2022 07:00 ET
|
Viridian Therapeutics, Inc.
- VRDN-002 incorporates clinically validated half-life extension technology to support development as a low volume subcutaneous injection -- Company expects to report top line VRDN-002 Phase 1...
Viridian Therapeutics Submits Investigational New Drug Application for VRDN-002 to the U.S. Food and Drug Administration
January 04, 2022 07:00 ET
|
Viridian Therapeutics, Inc.
- VRDN-002 is a novel anti-IGF-1R monoclonal antibody for thyroid eye disease and incorporates half-life extension technology designed to improve dosing and administration - - Company...
Viridian Therapeutics Announces First Subject Dosed in Phase 1/2 Clinical Trial of VRDN-001 for Thyroid Eye Disease (TED)
December 20, 2021 07:00 ET
|
Viridian Therapeutics, Inc.
- VRDN-001 targets and blocks IGF-1R, the only mechanism of action proven to deliver efficacy in TED -- Trial is on track to deliver top line proof of concept clinical data in 2Q 2022 - WALTHAM,...